Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Is there any contraindication for a patient receiving omalizumab for treatment of her lung aspergillosis to receive adjuvant breast radiotherapy?
Related Questions
What is your approach to women with breast cancer who opts for a staged approach with up-front lumpectomy and SLN biopsy (pN-) when there are indications for adjuvant radiation therapy but she plans for a later mastectomy (=>6 months)?
How does a pathological CR to neoadjuvant chemotherapy influence your practice for the use of bolus with adjuvant PMRT patients without inflammatory breast cancer, but who would meet traditional risk factors for skin involvement?
Would you offer partial breast radiation to a young breast cancer patient with BRCA 1 if all other criteria are met?
What is the maximum dose that you would give to residual unresectable gross disease in the axilla in the setting of recurrent breast cancer s/p ALND?
Would you offer PMRT to a patient with potential metastatic disease?
Would you consider omitting adjuvant radiation in a very elderly patient with a small triple negative breast cancer?
Does the presence of LCIS on pathology in a patient with IDC impact your decision to offer APBI?
Would you offer ultra-hypofractionated accelerated partial breast re-irradiation using 5 fractions?
Which patient subgroups do you plan to omit regional nodal irradiation for, given the publication of NSABP B-51?
Would a longstanding diagnosis of multiple sclerosis impact your radiation recommendations for a patient with breast cancer?
